Actively Recruiting
Mapping Heart Fibroblast Activation Using FAPI PETCT Imaging in Nonischemic Cardiomyopathy
Led by Peking Union Medical College Hospital · Updated on 2026-10-16
400
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the clinical value of 18FAlF-NOTA-FAPI-04 PETCT imaging for assessing myocardial fibroblast activation in patients with nonischemic cardiomyopathy. This condition includes diverse heart muscle disorders that lead to varying symptoms, treatment responses, and outcomes. The study focuses on determining if this imaging can enhance disease classification, treatment response evaluation, and risk prediction beyond current methods. Participants will receive an intravenous injection of up to 10 millicurie mCi of 18FAlF-NOTA-FAPI-04, followed by a PETCT scan to visualize active fibroblast processes in the heart. This imaging technique is expected to provide detailed patterns and quantitative measures of myocardial fibroblast activity. The study will correlate these findings with cardiac magnetic resonance imaging and echocardiography results, and assess changes up to 12 months after treatment adjustments. Throughout the study, participants will undergo baseline PETCT scans alongside cardiac MRI and echocardiography within 30 days of the PETCT. Follow-up assessments over up to 36 months will monitor changes in imaging uptake, heart function, and clinical outcomes such as mortality and cardiovascular events. The research will explore how this imaging method might support disease phenotyping, treatment monitoring, and prognosis in nonischemic cardiomyopathy.
CONDITIONS
Brief Title
FAPI PET Imaging in Nonischemic Cardiomyopathy
Research Team
L
Li Huo
X
Xuezhu Wang
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here